drugset / Trial / NCT00040521

Study Evaluating rhIL-11 in Active Crohn's Disease

NCT00040521

RandomizedDouble-blindTreatment

Summary

The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in patients with active Crohn's disease (Crohn's Disease Activity Index \[CDAI\] score from 220-400).

Timeline

Start
2002-04
Primary completion
2003-10
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Interleukin-11 Protein / enzyme biologic Oral

Indications